KRAS and non-small cell lung carcinoma: RAS mutation frequently occurs at exons 2 and 3, with the highest ratio identified at codons 12 and 13 of the KRAS gene in NSCLC, which are mainly gain-of-function alterations fostering oncogenic manners [19,20].